세계의 지혈제 및 조직 실링제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Hemostasis and Tissue Sealing Agents Market is presumed to reach the market size of nearly USD 19.31 Billion by 2032 from USD 8.52 Billion in 2023 with a CAGR of 9.51% under the study period 2024-2032.

Hemostasis and tissue sealing agents are medical products utilized to control bleeding and facilitate tissue repair during surgical procedures. These agents, including topical hemostats, sealants, and adhesives, are designed to quickly stop bleeding by promoting clot formation or sealing tissues. Commonly used in various surgical specialties, these agents can be derived from biological materials, such as collagen or fibrin, or be synthetic. Their primary function is to enhance surgical outcomes by reducing bleeding-related complications and promoting faster healing. These products are applied directly to the bleeding site or tissue interface to achieve effective hemostasis and secure tissue adhesion.

MARKET DYNAMICS

The hemostasis and tissue sealing agents market is fuelled by the increasing number of surgical procedures across diverse medical fields, including cardiovascular, orthopedic, and general surgery. The propelling demand for minimally invasive surgeries, which require effective hemostatic and sealing solutions to manage bleeding and enhance recovery, further supports market growth. Technological advancements, such as developing advanced sealant formulations with improved efficacy and biocompatibility, present significant opportunities. The focus on reducing surgical complications and improving patient outcomes through innovative hemostatic products drives market expansion. Additionally, the growing prevalence of chronic conditions and trauma cases that necessitate surgical intervention contributes to the increased use of these agents. With expanding healthcare infrastructure and surgical capabilities, emerging markets also offer growth potential for hemostasis and tissue sealing agents. However, high costs and potential allergic reactions may restrain the growth of hemostasis and tissue sealing agents.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hemostasis and Tissue Sealing Agents. The growth and trends of Hemostasis and Tissue Sealing Agents industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hemostasis and Tissue Sealing Agents market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Topical Hemostat (Active, Mechanical, Flowable)
• Adhesive & Tissue Sealant (Synthetic Tissue Sealant, Natural Tissue Sealant, Adhesion Barrier Products)

By Material

• Gelatin-Based Topical Hemostats
• Collagen-Based Topical Hemostats
• ORC-based Topical Hemostats
• Polysaccharide-Based Topical Hemostats

By Application

• General Surgery
• Neurosurgery
• Vascular Surgery
• Cardiovascular Surgery
• Others

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemostasis and Tissue Sealing Agents market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemostasis and Tissue Sealing Agents market include Johnson & Johnson, CryoLife Inc., Advance Medical Solution (AMS) Group Plc., Cohera Medical Inc., Integra Life Sciences Corporation, Pfizer Inc., BD, Baxter, HyperBranch Medical Technology, Biomet Inc, B Braun Medical Inc, Smith & Nephew. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. HEMOSTASIS AND TISSUE SEALING AGENTS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Material
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By End-use
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Topical Hemostat (Active, Mechanical, Flowable) Historic and Forecast Sales By Regions
• 5.4. Adhesive & Tissue Sealant (Synthetic Tissue Sealant, Natural Tissue Sealant, Adhesion Barrier Products) Historic and Forecast Sales By Regions

6. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS BY MATERIAL

• 6.1. Overview By Material
• 6.2. Historical and Forecast Data Analysis By Material
• 6.3. Gelatin-Based Topical Hemostats Historic and Forecast Sales By Regions
• 6.4. Collagen-Based Topical Hemostats Historic and Forecast Sales By Regions
• 6.5. ORC-based Topical Hemostats Historic and Forecast Sales By Regions
• 6.6. Polysaccharide-Based Topical Hemostats Historic and Forecast Sales By Regions

7. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. General Surgery Historic and Forecast Sales By Regions
• 7.4. Neurosurgery Historic and Forecast Sales By Regions
• 7.5. Vascular Surgery Historic and Forecast Sales By Regions
• 7.6. Cardiovascular Surgery Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-use
• 8.2. Historical and Forecast Data Analysis By End-use
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE HEMOSTASIS AND TISSUE SEALING AGENTS COMPANIES

• 10.1. Hemostasis and Tissue Sealing Agents Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF HEMOSTASIS AND TISSUE SEALING AGENTS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Johnson & Johnson
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. CryoLife Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Advance Medical Solution (AMS) Group Plc.
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Cohera Medical Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Integra Life Sciences Corporation
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Pfizer Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. BD
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Baxter
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. HyperBranch Medical Technology
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Biomet Inc
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. B Braun Medical Inc
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Smith & Nephew
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies